The shot is a hollow shell of nine HPV strains with no viral DNA inside, so it can't give you HPV; it just trains antibodies against the real virus. Six of the nine drive most cervical, anal, and throat cancers; two more cause about 90% of genital warts. It only blocks strains you haven't caught yet.
It works this late, if you're still naive. That 88.7% figure is for adults who finished the series naive to the strains 1; count people already infected and it falls to about 47%, because it can't rescue strains you carry. At population scale cervical cancer dropped 63% in vaccinated women 2. In men who have sex with men it stopped 75% of vaccine-type anal pre-cancer 3, and a 2024 US cohort saw HPV cancers in vaccinated men roughly halve 4.
What you're preventing isn't rare. Cervical cancer kills over 4,000 US women yearly. Throat cancer is the fastest-rising cancer in middle-aged US men, driven by HPV, peaking in the mid-2030s 5. The catch-up caveat: vaccinating at 35 buys less than at 12, since much of your exposure has already happened. Throat cancer is the exception, with 20-30 years from exposure to diagnosis.
The whole decision is one question: how much new sexual exposure is plausibly ahead of you? Future exposure tilts the math; your history barely does.
The cost trap is age 26. List price runs about $363 a shot, $1,089 uninsured, but most commercial plans cover Gardasil 9 with no copay. ACA preventive coverage is only mandated through 26; past that, payers vary and some want a documented indication, so call your insurer.
The fast payoff lands within weeks of dose three: your odds of new genital warts drop to essentially zero for the two strains behind about 90% of them 1. Over 5-10 years come fewer abnormal Paps and procedures 7. The cancers take 15-30 years to show lower rates 5.
The fine print — when to skip it, and what people get wrong
It won't treat what you already have. Warts, an abnormal Pap, a known lesion all still need their own care. And it isn't a substitute for Pap and HPV screening, which catch what it misses 6.
Skip in pregnancy: untested rather than known-harmful, and it waits well. Skip with severe yeast allergy; the vaccine is grown in baker's yeast. Don't redose after a severe reaction. Breastfeeding and mild illness are fine.
Two doses protect less than three in adults, so finishing matters. In HIV-positive adults 27+ the shot failed to prevent new anal infection — too much exposure was already behind them 8.
- 1Castellsague X, Munoz N, Pitisuttithum P, et al. (2011). End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. British Journal of Cancer. link
- 2Lei J, Ploner A, Elfström KM, et al. (2020). HPV Vaccination and the Risk of Invasive Cervical Cancer. New England Journal of Medicine. link
- 3Palefsky JM, Giuliano AR, Goldstone S, et al. (2011). HPV Vaccine against Anal HPV Infection and Anal Intraepithelial Neoplasia. New England Journal of Medicine. link
- 4Saxena K, Dawson R, Cyhaniuk A, et al. (2024). Effects of HPV vaccination on the development of HPV-related cancers: A retrospective analysis of a United States-based cohort. Journal of Clinical Oncology. link
- 5Damgacioglu H, Sonawane K, Zhu Y, et al. (2022). Long-term impact of HPV vaccination and COVID-19 pandemic on oropharyngeal cancer incidence and burden among men in the USA: A modeling study. The Lancet Regional Health - Americas. link
- 6CDC (2024). HPV Vaccine Recommendations. link
- 7Falcaro M, Castañon A, Ndlela B, et al. (2021). The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. The Lancet. link
- 8Wilkin TJ, Chen H, Cespedes MS, et al. (2018). A Randomized, Placebo-Controlled Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Adults Aged 27 Years or Older: AIDS Clinical Trials Group Protocol A5298. Clinical Infectious Diseases. link
დაკავშირებული სახელმძღვანელოში (4)
- — The shot blocks the virus; screening catches what slips through — you want both, not one.
- — The HPV catch-up shot prevents several of the cancers this schedule screens for, so it's worth doing alongside the checks.
- — HPV catch-up through 45 is one of the shots worth fitting into your adult schedule if you missed it young.
- — Another adult vaccine most people assume the age window closed on — it didn't, and it blocks six cancers.
HPV Vaccine: Adult Catch-Up
Three clinic or pharmacy visits over ~6 months; each takes under 15 minutes. No daily action required, no lifestyle change, no follow-up beyond completing the series (CDC 2024).
Gardasil 9 list price ~$363/dose, ~$1,089 for the three-dose series uninsured. Commercial insurance commonly covers it with $0 copay but variability is real in the 27-45 band where shared-decision-making framing applies (CDC 2024). Merck patient-assistance covers uninsured low-income adults. Net: $50-$500-equivalent burden for most insured adults; up to ~$1,000 one-time for fully out-of-pocket.
Pivotal RCT in adults aged 24-45 (Castellsague 2011) showed 88.7% per-protocol efficacy against the combined CIN/EGL endpoint; the 9-valent extension trial added 96.7% efficacy against the additional five high-risk types (Joura 2015). Population-register direct cancer-endpoint data from Sweden (Lei 2020) and England (Falcaro 2021) replicate the effect at scale. Catch-up-window-specific direct cancer endpoints in HIV-negative adults will not exist until ~2040, which is why this is 4 rather than 5.
Adult catch-up prevents cervical, anal, oropharyngeal, vulvar, vaginal, and penile cancers caused by vaccine HPV types; the Castellsague RCT (88.7% per-protocol against the combined HPV-6/11/16/18 endpoint, Castellsague 2011) and population register data (Lei 2020 cervical-cancer IRR 0.37) establish a real mortality-reduction effect. The score is 2 rather than 3-4 because the absolute lifetime cancer-risk reduction in the 27-45 catch-up window is meaningfully smaller than at age 11-12 — much exposure has already happened, and ACIP declined routine recommendation on cost-effectiveness grounds (Meites 2019).